19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace.

SCAMHC serves all individuals regardless of inability to pay. Discounts for essential services are offered based on family size and income. For more information, contact (334) 222-2523 or our 24/7 Helpline at 1-877-530-0002.

 

 


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
U.S. Teachers Often Faced Harassment, Violence During Pandemic: PollOmicron Wave Had 5 Times as Many Small Kids Hospitalized Compared to DeltaSuicide Rate Is Spiking Upwards in Preadolescent ChildrenAHA News: Bystander CPR on Kids Differs by Race and EthnicityNew Malaria Treatment Gets First Approval for Use in ChildrenMental Health of America's Children Only Getting WorseTalking to Your Kids About the War in UkraineOdds for Mental Illness Rise in Kids After ConcussionPfizer Begins Trial of COVID Drug Paxlovid in Kids 6 to 17Pfizer Vaccine Much Less Potent in Kids Aged 5-11COVID Has Robbed 5.2 Million Children Worldwide of Parent, CaregiverNew Drug May Help Curb COVID-Linked Inflammatory Disorder in KidsPoll Finds Most Parents Would Use CBD to Treat a Child — Is That Wise?Does Your Child Have Asthma? Look for the SignsResearch May Help Focus Treatment for Kids With Cystic FibrosisSleepless Children Often Become Sleepless Adults: StudyA Healthy Mouth Could Be a Lifesaver for Kids With Heart ConditionsSeasonal Flu Shots Give Kids Broader Protection Against New StrainsU.S. Kids Still Dying From Toppling TVs, FurnitureKids With COVID-Linked MIS-C Have Long-Term SymptomsAHA News: Amid a National Mental Health Crisis For Kids, Here's How Parents Can HelpParents: What You Need to Know About Kids & COVID-19Getting Active Soon After Concussion May Aid Kids' RecoveryPfizer Asks FDA to Approve Its Vaccine for Youngest KidsThe 'Oreo Test' and Other Ways to Help Kids' Oral HealthPfizer Will Ask FDA to Approve Its COVID Vaccine for Kids Under 5Getting Your School-Age Child Into a Healthy Sleep RoutineGenes Could Help Drive Febrile Convulsions in KidsMore Than 1 Million U.S. Kids Diagnosed With COVID in Single WeekPandemic Especially Tough on Kids With ADHDBrain Implant for Adults With Epilepsy Can Help Kids, TooCOVID Can Affect Brains of Hospitalized KidsMany Kids Aren't Wearing Helmets While Sledding, Poll FindsMany Marijuana Vendors Aim Advertising at Kids: StudyHeart Function Rebounds for Kids With COVID-Linked MIS-CWhich Kids Are Most Vulnerable to Severe COVID-19?At-Home COVID Tests Accurate for Ki​ds: StudyCDC Study Shows Power of Flu Vaccine for KidsCOVID Hospitalizations Rising in Kids Too Young for VaccineNearly 600,000 U.S. Kids Had COVID Last WeekWhite House to Give Schools 10 Million Free COVID Tests Every MonthKids' Behavior Worsened With Remote Learning: StudyLater School Start Times Boost Parents' Health, TooUrban Air Pollution Drives Millions of Cases of Asthma in KidsCDC Backs Boosters for High-Risk Kids Aged 5-11, Shorter Time Between ShotsA Better Way to Correct Severe Scoliosis in Kids?Getting Your Child Their Vaccine?  Some Tips on Easing Needle FearsU.S. Hospitals Seeing Record Numbers of Young COVID PatientsSevere Illness in Children Brings Hardship for FamiliesReal-World Data Confirms Pfizer Vaccine Safe for Kids Ages 5-11
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

New Drug May Help Curb COVID-Linked Inflammatory Disorder in Kids


HealthDay News
Updated: Feb 24th 2022

new article illustration

THURSDAY, Feb. 24, 2022 (HealthDay News) -- A drug developed for an autoimmune disease shows promise in treating a potentially life-threatening inflammatory condition in children who've had COVID-19, researchers say.

The rare condition is called multisystem inflammatory syndrome in children (MIS-C). It typically develops weeks to months after a child has had mild or even asymptomatic COVID-19.

"Working collaboratively, we've been able to demonstrate that viral particles that remain in the gut long after COVID-19 infection can instigate MIS-C," said study co-author David Walt. He is a principal investigator in the pathology department at Brigham and Women's Hospital in Boston.

"Building on this important discovery, we wanted to see if treatment with a drug developed for another condition — celiac disease — could help resolve symptoms in children experiencing MIS-C," Walt said in a hospital news release.

MIS-C causes fever and hyperinflammation that can affect multiple organs, including the heart, brain and gastrointestinal tract.

Fifty-five children out of over 6,400 diagnosed with MIS-C have died since May 2020, according to the U.S. Centers for Disease Control and Prevention.

The researchers applied to the U.S. Food and Drug Administration in February 2021 for emergency compassionate use of the drug larazotide acetate to treat MIS-C.

The doctors gave the drug to four extremely ill children, aged 3 to 17, being treated for MIS-C at Massachusetts General Hospital. Larazotide decreases the release of a molecule called zonulin, which increases the risk that the highly inflammatory spike protein associated with COVID-19 can escape the gut and get into the bloodstream.

The four children who received four daily oral doses of larazotide acetate also received steroids and intravenous immune globulin (IVIG). They were compared to 22 children with MIS-C who received only steroids and IVIG.

Compared to those who didn't receive larazotide, the children who got the drug had a much quicker recovery from gastrointestinal symptoms such as stomach pain, vomiting and diarrhea, and also had slightly shorter hospital stays.

The spike protein associated with the coronavirus cleared from the blood of children treated with larazotide within one day, compared to 10 days for the children who weren't given the drug, according to the study.

"These findings suggest that larazotide may provide a safe and beneficial adjuvant therapy for the treatment of MIS-C," the study authors concluded.

The results were published online recently in the journal Critical Care Explorations.

Larazotide is currently in a phase 3 clinical trial for approval to treat celiac disease, an autoimmune disease that leads to damage in the small intestine.

More information

For more on MIS-C, go to the U.S. Centers for Disease Control and Prevention.

SOURCE: Massachusetts General Hospital and Brigham and Women's Hospital, news release, Feb. 23, 2022